Prestige Consumer Healthcare (NYSE:PBH) vs. Metastat (OTCMKTS:MTST) Head to Head Survey

Prestige Consumer Healthcare (NYSE:PBH) and Metastat (OTCMKTS:MTST) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation and dividends.

Earnings & Valuation

This table compares Prestige Consumer Healthcare and Metastat”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prestige Consumer Healthcare	$1.14 billion	2.69	$214.60 million	$4.03	15.80
Metastat	N/A	N/A	N/A	N/A	N/A

Prestige Consumer Healthcare has higher revenue and earnings than Metastat.

Analyst Ratings

This is a summary of current ratings and recommmendations for Prestige Consumer Healthcare and Metastat, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prestige Consumer Healthcare	0	4	4	0	2.50
Metastat	0	0	0	0	0.00

Prestige Consumer Healthcare presently has a consensus target price of $85.33, suggesting a potential upside of 34.03%. Given Prestige Consumer Healthcare’s stronger consensus rating and higher probable upside, research analysts plainly believe Prestige Consumer Healthcare is more favorable than Metastat.

Risk and Volatility

Prestige Consumer Healthcare has a beta of 0.39, suggesting that its stock price is 61% less volatile than the S&P 500. Comparatively, Metastat has a beta of 282.06, suggesting that its stock price is 28,106% more volatile than the S&P 500.

Profitability

This table compares Prestige Consumer Healthcare and Metastat’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Prestige Consumer Healthcare	18.09%	12.43%	6.67%
Metastat	N/A	N/A	N/A

Institutional and Insider Ownership

100.0% of Prestige Consumer Healthcare shares are held by institutional investors. 1.4% of Prestige Consumer Healthcare shares are held by insiders. Comparatively, 8.5% of Metastat shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Prestige Consumer Healthcare beats Metastat on 8 of the 10 factors compared between the two stocks.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.

About Metastat

MetaStat, Inc., a precision medicine company, focuses on discovering and developing therapeutic and diagnostic treatment solutions for cancer patients. The company is developing novel drug candidates and companion diagnostic tests that target the MENA pathway. Its product candidates include MENA diagnostic assay, a tissue-based quantitative immunofluorescence test that measures expression of the pro-metastatic MENA protein splice-variant; companion diagnostic to predict RTK inhibitor drug responses and anti-microtubule drug responses; liquid blood-based biopsy to enhance cancer diagnosis and optimize patient care; MetaSite Breast assay, an immunohistochemistry test that measures micro-anatomical intravasat at blood vessels within the tumor microenvironment ion sites; and prognostic diagnostic to predict risk of cancer metastasis. The company’s therapeutic targets a critical metastatic pathway in solid tumors responsible for driving tumor resistance and the spread of aggressive cancer. MetaStat, Inc. is based in Boston, Massachusetts.